Itching For Relief: The Evidence Of Fixed Dose Calcipotriol Plus Betamethasone Dipropionate Foam For Psoriasis

Abstract

Psoriasis is a chronic immune-mediated skin disease with a variety of morphological presentations, distribution patterns and severities. Psoriasis can have a profound impact on health-related quality of life (HRQoL), almost equal to that seen in patients suffering from cardiovascular disease and cancer. In Canada, it is estimated that approximately 3% of the population suffers from psoriasis, equating to over 1 million people. The most common presentation is ‘mild-to-moderate’ plaque psoriasis characterized by well-defined silver scaly plaques on extensor surfaces. However, classifying severity can be challenging. In 2020, the International Psoriasis Council recommended classifying psoriasis severity with a dichotomous definition: either candidates for topical therapy or candidates for systemic therapy. Regardless of severity, all patients living with psoriasis will need a topical agent as part of their treatment regimen throughout the clinical course of their disease.